


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (original) A tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative having the general Formula I



Formula I

Wherein

X is CH₂, O or S;

R represents 1-3 substituents independently selected from H, (C₁₋₄)alkyl, (C₁₋₄)alkyloxy and halogen;

R₁ is (C₅₋₈)cycloalkyl;

R₂ is H or (C₁₋₄)alkyl;

R₃, R_{3'}, R₄, R_{4'}, R₅, R_{5'} and R₆' are independently hydrogen or (C₁₋₄)alkyl, optionally substituted with (C₁₋₄)alkyloxy, OH or halogen;

R₆ is hydrogen or (C₁₋₄)alkyl, optionally substituted with (C₁₋₄)alkyloxy, OH or halogen; or

R₆ forms together with R₇ a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S;

R₇ forms together with R₆ a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S; or

R₇ is H, (C₁₋₄)alkyl or (C₃₋₅)cycloalkyl, the alkyl groups being optionally substituted with OH, halogen or (C₁₋₄)alkyloxy; or a pharmaceutically acceptable salt thereof.

2. (original) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1, wherein R is H and R₁ is cyclopentyl or cyclohexyl.

3. (currently amended) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1 [or 2], wherein X is CH₂ or O.

4. (currently amended) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of [any one of claims 1-3] claim 1, wherein R, R₂, R₃, R₃', R₄', R₅, R₅' and R₆' are H; R₄, R₆ and R₇ are independently H or (C₁₋₄)alkyl; or R₆ forms together with R₇ a 5- or 6-membered saturated heterocyclic ring and R₄ is H or (C₁₋₄)alkyl.
5. (cancelled)
6. (currently amended) A pharmaceutical composition comprising a tricyclic 1-[(indol-3-yl)-carbonyl]piperazine derivative of [any one of claims 1-4] claim 1 together with a pharmaceutically acceptable carrier therefor.
7. (cancelled)
8. (new) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 2, wherein X is CH₂ or O.
9. (new) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 2, wherein R, R₂, R₃, R₃', R₄', R₅, R₅' and R₆' are H; R₄, R₆ and R₇ are independently H or (C₁₋₄)alkyl; or R₆ forms together with R₇ a 5- or 6-membered saturated heterocyclic ring and R₄ is H or (C₁₋₄)alkyl.
10. (new) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 3, wherein R, R₂, R₃, R₃', R₄', R₅, R₅' and R₆' are H; R₄, R₆ and R₇ are independently H or (C₁₋₄)alkyl; or R₆ forms together with R₇ a 5- or 6-membered saturated heterocyclic ring and R₄ is H or (C₁₋₄)alkyl.
11. (new) A method of treating pain in a patient in need of such treatment, comprising:
administering an effective amount of the compound according to claim 1.
12. (new) A method of activating a cannabinoid CB1 receptor in a patient in need thereof, comprising:
administering an effective amount of the compound according to claim 1.